Shanghai Junshi Biosciences logo

Shanghai Junshi Biosciences(SEHK) 1877

Market CapHK$16.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-31%
5 Year-60%
1 Year-39%
1 Month-4%
HK$16.31
+0.80%
+0.13Today
Shanghai Junshi Biosciences last closing stock price
MetricPriceDate
Last closeHKD 16.312026-10-16
Shanghai Junshi Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.59%HKD 17.652026-10-09
1 month-3.95%HKD 16.982026-09-16
3 month-7.54%HKD 17.642026-07-17
Year to date-23.57%HKD 21.342025-12-31
1 year-38.96%HKD 26.722025-10-16
3 year-11.93%HKD 18.522023-10-17
5 year-60.22%HKD 41.002021-10-15
Since inception-31.33%HKD 23.752018-12-24

Shanghai Junshi Biosciences Financials at a Glance

Market Cap

HK$16.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥3.01B

Net Income (TTM)

-CN¥435.91M

EPS (TTM)

-HK$0.47

P/E Ratio

-34.78

Dividend

HK$0.00

Beta (Volatility)

0.02 (Low)

Price

HK$16.31

Volume

1,201,400

Open

HK$16.45

Previous Close

HK$16.18

Daily Range

HK$16.14 - HK$16.89

52-Week Range

HK$15.25 - HK$30.80

Estimated Earnings Date

Oct 30, 2026

1877 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shanghai Junshi Biosciences

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm dedicated to the research, development, and marketing of innovative pharmaceutical products. The company operates primarily in the People's Republic of China, focusing on various therapeutic areas including oncology, metabolic disorders, autoimmune conditions, neurological ailments, and infectious diseases.

Products and Services
  • JS001 (TUOYI): Anti-PD-1 monoclonal antibody for multiple cancers
  • UBP1211: Biosimilar of Humira for rheumatoid arthritis and psoriasis
  • JS002: Anti-PCSK9 monoclonal antibody targeting hyperlipidemia
Growth Outlook
  • Strong pipeline with multiple monoclonal antibodies in development
  • Partnerships with Eli Lilly and Coherus Biosciences enhance market reach
  • Increasing demand for innovative therapies in China supports growth
Financial Highlights
  • Q2 2026 revenue of CNY 965.8 million, up from CNY 719.7 million in Q1 2026
  • Gross profit margin improved to 81.3% in Q2 2026
  • Cash and short-term investments totaled CNY 3.7 billion as of June 2026
Shanghai Junshi Biosciences Co., Ltd. has established itself as a key player in the biotechnology sector, with a robust portfolio of products aimed at addressing significant health challenges. The company's flagship product, JS001, has gained traction in the oncology market, while its biosimilars and other monoclonal antibodies are poised to capture additional market share. Recent financial performance indicates a positive trend, with substantial revenue growth and a strong gross profit margin, reflecting effective cost management and operational efficiency. The strategic partnerships with established pharmaceutical companies further bolster the company's position, providing access to advanced technologies and broader distribution channels. As the demand for innovative biopharmaceuticals continues to rise, Shanghai Junshi Biosciences is well-positioned to capitalize on emerging opportunities in the healthcare landscape.
AI Generated • Oct 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2,903

CEO

Cong Li; Jian Jun Zou, PhD

Website

www.junshipharma.com

Headquarters

Shanghai, SH 200126, CN

1877 Financials

Key Financial Metrics (TTM)

Gross Margin

79.86%

Operating Margin

-22.40%

Net Income Margin

-14.57%

Return on Equity

-7.32%

Return on Capital

-8.94%

Return on Assets

-3.09%

Earnings Yield

-2.88%

Dividend Yield

0.00%

Payout Ratio

-16.88%

Stock Overview

Market Cap

HK$16.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.02B

Volume

1.20M

Avg. Volume

2.48M

Financials (TTM)

Gross Profit

CN¥2.39B

Operating Income

-CN¥609.74M

EBITDA

-CN¥350.52M

Operating Cash Flow

-CN¥214.54M

Capital Expenditure

-CN¥796.33M

Free Cash Flow

-CN¥1.01B

Cash & ST Invst.

CN¥3.70B

Total Debt

CN¥5.91B

Shanghai Junshi Biosciences Performance Analysis

Shanghai Junshi Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 1,691,172,196-65.2%
20232023-12-31CNY 1,655,393,817-2.1%
20242024-12-31CNY 2,105,905,68127.2%
20252025-12-31CNY 2,700,220,52528.2%
Shanghai Junshi Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.6%
Q42025-12-317.1%
Q12026-03-315.5%
Q22026-06-3034.2%
Shanghai Junshi Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -3.02209.7%
20232023-12-31CNY -2.56-15.2%
20242024-12-31CNY -1.41-45.0%
20252025-12-31CNY -0.94-33.1%
Shanghai Junshi Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.6%
Q42025-12-31-47.1%
Q12026-03-3192.1%
Q22026-06-30307.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥965.80M

+44.6%

Gross Profit

CN¥784.80M

+53.5%

Gross Margin

81.26%

N/A

Market Cap

HK$16.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$5.47M

N/A

Employees

3,055

N/A

Net Income

CN¥42.05M

+123.6%

EBITDA

CN¥36.25M

+130.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥3.70B

+5.4%

Total Debt

CN¥5.91B

+69.2%

Accounts Receivable

CN¥866.94M

+64.7%

Inventory

CN¥498.73M

-10.4%

Long Term Debt

CN¥4.47B

+142.0%

Short Term Debt

CN¥1.44B

-12.4%

Return on Assets

-3.09%

N/A

Return on Invested Capital

-5.96%

N/A

Free Cash Flow

-CN¥193.93M

+57.6%

Operating Cash Flow

-CN¥104.09M

+65.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,659.44-0.01%
^DJIDJI
$52,002.41-0.00%
^IXICNASDAQ
$26,140.03-0.02%
BTCBitcoin
$81,471.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About 1877

What is the current price of Shanghai Junshi Biosciences?

Shanghai Junshi Biosciences is trading at HK$16.31 per share.

What is the 52-week range for Shanghai Junshi Biosciences?

Over the past 52 weeks, Shanghai Junshi Biosciences has traded between HK$15.25 and HK$30.80.

How much debt does Shanghai Junshi Biosciences have?

As of the most recent reporting period, Shanghai Junshi Biosciences reported total debt of CN¥6.83B.

How much cash does Shanghai Junshi Biosciences have on hand?

Shanghai Junshi Biosciences reported CN¥3.16B in cash and cash equivalents in its most recent financial results.

What is Shanghai Junshi Biosciences’s dividend yield?

Shanghai Junshi Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services